Payment overview · 2025
General Payments
$691.22
23 reported records · 9 companies
Healthcare provider profile · identity verified
Alan Katz, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MELBOURNE, FL · NPI 1861489023
Verified facts
What the public records show
CMS Open Payments records show Alan Katz, M.D. received $691.22 in general payments during 2025 across 23 reported records.
CVRx, Inc. accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CVRx, Inc. | Unresolved — no canonical attribution shown | $179.74 | 26.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $140.70 | 20.4% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $117.72 | 17.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $78.94 | 11.4% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.37 | 8.4% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$42.17 | 6.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.35 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.79 | 4.0% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $15.44 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $691.22 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $179.74 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $140.70 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $117.72 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $99.64 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.37 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $57.41 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.60 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.35 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.35 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 154 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
154 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 576 | 202 |
| Amlodipine Besylate | Amlodipine Besylate | 510 | 171 |
| Losartan Potassium | Losartan Potassium | 458 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 442 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 109 |
| Metformin Hcl | Metformin Hcl | 250 | 87 |
| Lisinopril | Lisinopril | 247 | 89 |
| Gabapentin | Gabapentin | 224 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 64 |
| Pioglitazone Hcl | Pioglitazone Hcl | 176 | 61 |
| Alprazolam | Alprazolam | 172 | 41 |
| Omeprazole | Omeprazole | 160 | 56 |
| Ozempic | Semaglutide | 154 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 51 |
| Tramadol Hcl | Tramadol Hcl | 110 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 33 |
| Eliquis | Apixaban | 101 | 29 |
| Trazodone Hcl | Trazodone Hcl | 98 | 39 |
| Tresiba Flextouch U-100 | Insulin Degludec | 97 | 25 |
| Famotidine | Famotidine | 95 | 30 |
| Furosemide | Furosemide | 95 | 34 |
| Metformin Hcl Er | Metformin Hcl | 94 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 32 |
| Carvedilol | Carvedilol | 85 | 29 |
| Pregabalin | Pregabalin | 85 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 32 |
| Ezetimibe | Ezetimibe | 76 | 24 |
| Sertraline Hcl | Sertraline Hcl | 76 | 31 |
| Jardiance | Empagliflozin | 73 | 23 |
| Glimepiride | Glimepiride | 69 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 23 |
| Spironolactone | Spironolactone | 66 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 24 |
| Glipizide | Glipizide | 63 | 25 |
| Lorazepam | Lorazepam | 63 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 52 |
| Temazepam | Temazepam | 57 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 18 |
| Montelukast Sodium | Montelukast Sodium | 54 | 23 |
| Meloxicam | Meloxicam | 53 | 20 |
| Mirtazapine | Mirtazapine | 52 | 18 |
| Allopurinol | Allopurinol | 51 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Finasteride | Finasteride | 49 | 19 |
| Xarelto | Rivaroxaban | 49 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 34 |
| Prednisone | Prednisone | 48 | 26 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 36 |
| Simvastatin | Simvastatin | 44 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 18 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Azithromycin | Azithromycin | 37 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 11 |
| Donepezil Hcl | Donepezil Hcl | 36 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | 14 |
| Baclofen | Baclofen | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 21 |
| Valacyclovir | Valacyclovir Hcl | 28 | 16 |
| Meclizine Hcl | Meclizine Hcl | 27 | 12 |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 12 |
| Tresiba | Insulin Degludec | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 17 |
| Valsartan | Valsartan | 24 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $691.22 · 23 records | CVRx, Inc. | Arikayce, BREZTRI, Barostim Neo System, INCEPTIV, INTELLIS ADAPTIVESTIM, JARDIANCE, MOUNJARO, OFEV, Ozempic, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error